Uniswift Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.80 M
- Company Age 5 Year, 3 Months
- Last Filing with ROC 31 Mar 2021
About Uniswift Pharmaceuticals
Uniswift Pharmaceuticals Private Limited (UPPL) is a Private Limited Indian Non-Government Company incorporated in India on 01 November 2019 (Five years and three months 5 days old ). Its registered office is in Bangaluru, Karnataka, India.
The Company is engaged in the Trading Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2021. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.80 M, as per Ministry of Corporate Affairs (MCA) records.
Kangaparambil Manoj, Perinkulam Krishnan, Ramakrishnan Madhusoodanan, and One other member serve as directors at the Company.
Company Details
-
Location
Bangaluru, Karnataka, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U51909KA2019PTC129263
-
Company No.
129263
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
01 Nov 2019
-
Date of AGM
30 Nov 2021
-
Date of Balance Sheet
31 Mar 2021
-
Listing Status
Unlisted
-
ROC Code
Roc Bangalore
Industry
Who are the key members and board of directors at Uniswift Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Perinkulam Krishnan
|
Managing Director | 01-Nov-2019 | Current |
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
|
Kangaparambil Manoj
|
Director | 11-Mar-2022 | Current |
|
Ramakrishnan Madhusoodanan
|
Director | 01-Nov-2019 | Current |
|
Kochiyil Vijayan
|
Director | 11-Mar-2022 | Current |
Financial Performance of Uniswift Pharmaceuticals.
Uniswift Pharmaceuticals Private Limited, for the financial year ended 2020, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Uniswift Pharmaceuticals?
Unlock access to Uniswift Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
-
Environ Pharmaceuticals Private LimitedKangaparambil Manoj is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Uniswift Pharmaceuticals?
Unlock and access historical data on people associated with Uniswift Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Uniswift Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Uniswift Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
